Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Sullivan

Showing results (281-290 of 328) with videos related to

Pageof 33
Sort By:
Nature Communications|January 2, 2025
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis productAvanish Mishra, Shih-Bo Huang, Taronish Dubash, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid TumorsRyan B Corcoran, Khanh T Do, Jeong E Kim, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2024
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis productAvanish Mishra, Shih-Bo Huang, Taronish Dubash, et al.
Nature Communications|June 24, 2026
Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistanceSamuel J Wright, Izabella Zamora, Milan Parikh, et al.
The Oncologist|March 3, 2021
Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018Gabriel E Molina, Leyre Zubiri, Justine V Cohen, et al.
JAMA Oncology|April 29, 2016
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical TrialGuo Chen, Jennifer L McQuade, David J Panka, et al.
Nature Communications|October 27, 2017
Resistance to checkpoint blockade therapy through inactivation of antigen presentationMoshe Sade-Feldman, Yunxin J Jiao, Jonathan H Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 MonotherapyXue Bai, Jiani Hu, Allison Betof Warner, et al.
JAMA Oncology|July 17, 2015
Rapid Intraoperative Molecular Characterization of GliomaGanesh M Shankar, Joshua M Francis, Mikael L Rinne, et al.
Nature|September 28, 2017
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomasHezhe Lu, Shujing Liu, Gao Zhang, et al.
Pageof 33

Showing results (281-290 of 328) with videos related to

Sort By:
Pageof 33
Nature Communications|January 2, 2025
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis productAvanish Mishra, Shih-Bo Huang, Taronish Dubash, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid TumorsRyan B Corcoran, Khanh T Do, Jeong E Kim, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2024
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis productAvanish Mishra, Shih-Bo Huang, Taronish Dubash, et al.
Nature Communications|June 24, 2026
Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistanceSamuel J Wright, Izabella Zamora, Milan Parikh, et al.
The Oncologist|March 3, 2021
Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018Gabriel E Molina, Leyre Zubiri, Justine V Cohen, et al.
JAMA Oncology|April 29, 2016
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical TrialGuo Chen, Jennifer L McQuade, David J Panka, et al.
Nature Communications|October 27, 2017
Resistance to checkpoint blockade therapy through inactivation of antigen presentationMoshe Sade-Feldman, Yunxin J Jiao, Jonathan H Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 MonotherapyXue Bai, Jiani Hu, Allison Betof Warner, et al.
JAMA Oncology|July 17, 2015
Rapid Intraoperative Molecular Characterization of GliomaGanesh M Shankar, Joshua M Francis, Mikael L Rinne, et al.
Nature|September 28, 2017
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomasHezhe Lu, Shujing Liu, Gao Zhang, et al.
Pageof 33